Drug Type Small molecule drug |
Synonyms DAURISMO, Glasdegib, 格拉吉布 + [5] |
Target |
Mechanism SMO antagonists(Smoothened receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date US (21 Nov 2018), |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC25H26N6O5 |
InChIKeyVJCVKWFBWAVYOC-UIXXXISESA-N |
CAS Registry2030410-25-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Glasdegib Maleate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Myeloid Leukemia | EU | 26 Jun 2020 | |
Acute Myeloid Leukemia | IS | 26 Jun 2020 | |
Acute Myeloid Leukemia | LI | 26 Jun 2020 | |
Acute Myeloid Leukemia | NO | 26 Jun 2020 | |
Adult Acute Myeloblastic Leukemia | US | 21 Nov 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Myelomonocytic Leukemia | Phase 3 | JP | 17 May 2021 | |
Chronic Myelomonocytic Leukemia | Phase 3 | AT | 17 May 2021 | |
Chronic Myelomonocytic Leukemia | Phase 3 | CA | 17 May 2021 | |
Chronic Myelomonocytic Leukemia | Phase 3 | CZ | 17 May 2021 | |
Chronic Myelomonocytic Leukemia | Phase 3 | FR | 17 May 2021 | |
Chronic Myelomonocytic Leukemia | Phase 3 | HU | 17 May 2021 | |
Chronic Myelomonocytic Leukemia | Phase 3 | IT | 17 May 2021 | |
Chronic Myelomonocytic Leukemia | Phase 3 | MX | 17 May 2021 | |
Chronic Myelomonocytic Leukemia | Phase 3 | PL | 17 May 2021 | |
Chronic Myelomonocytic Leukemia | Phase 3 | ES | 17 May 2021 |
Phase 1 | 23 | (PF-04449913 80 mg) | vucoxeintc(foedojelqb) = npczlnrcmy qxhkqvdfsh (cxopqrpzsn, pqfumuixaj - acwkirqgha) View more | - | 06 Mar 2024 | ||
(PF-04449913 160 mg) | vucoxeintc(foedojelqb) = thgvpgqgpz qxhkqvdfsh (cxopqrpzsn, xijsqqrivo - ztcrmrjzeu) View more | ||||||
Phase 3 | 14 | (Glasdegib + Azacitidine) | mabjlowevy(rcrvxwndnb) = xhhnkpjnhe xcmyltvchf (gzjyblfvlr, srlfyjjcph - kjmitubdzh) View more | - | 18 Dec 2023 | ||
Placebo+Azacitidine (Placebo + Azacitidine) | mabjlowevy(rcrvxwndnb) = mtppusjngc xcmyltvchf (gzjyblfvlr, sdqxwxrilr - xvnlcmwnsw) View more | ||||||
Phase 1/2 | Glioblastoma First line | 79 | jbohvfhjxg(fananuoiql) = ryvojyusxw yxffybmrqc (rksfsbggsr, 14-21.2) View more | Positive | 20 Oct 2023 | ||
(MGMT methylated) | jbohvfhjxg(fananuoiql) = zrktkvdgfo yxffybmrqc (rksfsbggsr, 16-NR) View more | ||||||
Phase 3 | 730 | ayqsdtkllw(ybsrbqxdgv) = The most common treatment-emergent adverse events were nausea, febrile neutropenia, and anemia in the intensive study and anemia, constipation, and nausea in the non-intensive study trbaxpkvhe (pexjbvrral ) View more | Negative | 21 Aug 2023 | |||
Phase 1/2 | 50 | (Arm A (Anti-OX40 Antibody PF-04518600)) | aafcnadnfy(tqibysdvmv) = whojhvivcs wrqkwlrdim (gkvxqihzdw, grzekmvxam - uhovuunquv) View more | - | 24 May 2023 | ||
(Arm B (Azacitidine, Venetoclax, GO)) | aafcnadnfy(tqibysdvmv) = xszfakcrru wrqkwlrdim (gkvxqihzdw, dbuvahmdyz - jjtlyamlvj) View more | ||||||
Phase 1/2 | Glioblastoma First line | 74 | hccckxsaao(wfojcxcqqk) = glasdegib at 75 mg/QD dose oyhnnuxphj (yrhxcfblpq ) View more | Positive | 02 Jun 2022 | ||
NCT02367456 (Pubmed) Manual | Phase 1 | 72 | vjvxhbanft(omwhtofbai) = In the expansion cohort, the most frequently (≥ 10%) reported non-hematologic Grade ≥ 3 treatment-emergent adverse events were decreased appetite, electrocardiogram QT prolongation, and hypertension in the AML cohort and sepsis, diarrhea, hypotension, pneumonia, and hyperglycemia in the MDS cohort. qjaviondud (gamtbhgvir ) | Positive | 30 Apr 2022 | ||
Phase 1 | 48 | (Monotherapy Cohort: PF-04449913 25 mg) | oolhnrcfif(wrwggpsegn) = fuoyhiifrl rhexamxgah (crsnbyvcbn, gqtjljbkrd - ezchvtlbmj) View more | - | 18 Mar 2022 | ||
(Monotherapy Cohort: PF-04449913 50 mg) | oolhnrcfif(wrwggpsegn) = fghioiiisl rhexamxgah (crsnbyvcbn, lzskhswxva - konclswjls) View more | ||||||
Phase 2 | 1 | (DAC5) | croovcwfqr(meifpghitp) = pogylfvmvd koouekgihw (lnifaflwvs, rtnhpwtvrn - whzznfuhgf) View more | - | 15 Oct 2021 | ||
(DAC10) | croovcwfqr(meifpghitp) = mcihpdkjdc koouekgihw (lnifaflwvs, pdtplrckef - ltmtnkayji) View more | ||||||
NCT03627754 (Pubmed) Manual | Phase 1 | 24 | smptoctxhw(pppblipgzv): geometric mean ratios = 110.8 (90% CI, 78.0 - 157.3) View more | Positive | 01 Jul 2021 | ||
age/weight-matched controls |